Nanjing Immunophage Biotech

Biologics (private)

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
EBI2Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
November 2028 (1)
IPG11406Phase 2Lupus Nephritis
Est. primary completion 2028-11-20 · NCT07937501 · CT.gov ↗
What to watch
December 2028 (1)
IPG11406Phase 2Moderately to Severely Active Ulcerative Colitis (UC)
Est. primary completion 2028-12-01 · NCT07535489 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.